We have introduced
chimeric genes which express GFP in a variety of organelles within the plant cell in order to study the dynamics of cell organization.
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin - T - cell receptor chimeric molecules as functional receptors with antibody - type specificity (
chimeric genes / antibody variable region).
Not exact matches
US - based pharmaceutical company Gilead Sciences entered the
chimeric antigen receptor (CAR) T - cell therapy business through its acquisition of Kite Pharma, and Australian biopharma company CSL Behring acquired US - based Calimmune, a company that develops clinical - stage
gene therapy solutions.
Kawaoka and his team, whose work has been accepted by Nature, created a
chimeric virus with the hemagglutinin protein from H5N1 and the
genes from the 2009 pandemic strain of H1N1.
Through
gene therapy, researchers engineered blood - forming stem cells (hematopoietic stem / progenitor cells, or HSPCs) to carry
chimeric antigen receptor (CAR)
genes to make cells that can detect and destroy HIV - infected cells.
Extracts from the brains of FFI patients transmitted disease to transgenic mice expressing a
chimeric human - mouse PrP
gene about 200 days after inoculation and induced formation of the 19 - kilodalton PrPSc fragment, whereas extracts from the brains of familial and sporadic Creutzfeldt - Jakob disease patients produced the 21 - kilodalton PrPSc fragment in these mice.
T - cells can be programmed to recognise these by giving them
genes for tailor - made receptors called
chimeric antigen receptors (CARs).
Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target
genes.
The UK patents relate to the CRISPR - Cas9
gene editing systems involving single - guide RNA in both non-cellular and cellular settings (UK Patent No. 2518764) and
chimeric CRISPR - Cas9 systems in which the Cas9 protein is modified to provide alternative DNA - modulating activities (UK Patent No. 2537000).
CAR - T immunotherapy involves genetically outfitting a patient's immune cells with a new artificial
gene, a
chimeric antigen receptor (CAR), which allows the cells to recognize and attack specific cancer cells.
The proposed
gene therapy is based on the success of small human trials of killer T - cells (
Chimeric Antigen Receptor [CAR] T - cell therapy).
Hanner and Rusche used chromatin immunoprecipitation assays to show that this
chimeric protein did not make it to the HMRa or HMRα loci or to other repressed
genes.
In bacteria, the ligand - PBP complex develops high affinity for transmembrane proteins such as Trg, and the
chimeric Trg - HK protein allows activation of
gene expression with one additional protein, a bacterial response regulator [5].
This
chimeric Trg - HK protein allows input from the re-designed receptors to be linked to
gene expression [5].
Interestingly, the
chimeric mice can be directly used to monitor tumor development as they contain the same genetic alterations as the original GEMM including the altered target
gene expression.
Spontaneous expansion of the CAG repeat stretch in the CAG 140 KI mouse model, which carries a
chimeric mouse / human exon 1 containing around 125 CAG repeats and the human polyproline region inserted in the murine huntingtin
gene (Menalled et al., 2003, Hickey et al., 2008), has recently led to a new KI line that carries around 190 CAG repeats (CAG 190 KI) in a congenic C57Bl / 6J background.
The CAG 140 KI mouse model carries a
chimeric mouse / human exon 1 containing around 125 CAG repeats and the human polyproline region inserted in the murine huntingtin
gene.
First, they remain in the offspring after birth and are related to the HLA
genes, and second,
chimeric cells are not merely present in the children — but they are active, as shown by the attacks they mount against the child's body.